Behavioral and cognitive effects of the N-methyl-d-aspartate receptor co-agonist d-serine in healthy humans: Initial findings

Journal of Psychiatric Research

Volumn 61, Issue , 2015, Pages 188-195

  Levin, Raz ^a   Dor Abarbanel, Adi Ein ^b   Edelman, Shany ^b   Durrant, Andrea R ^a   Hashimoto, Kenji ^c   Javitt, Daniel C ^d   Heresco Levy, Uriel ^a,b  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c CHIBA UNIVERSITY   (Japan)

^d Columbia University ^*  (United States)

Author keywords

Behavior; Cognition; D serine; N methyl d aspartate receptor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DEXTRO SERINE; GLYCINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; GLUTAMIC ACID; SERINE;

ACUTE DRUG ADMINISTRATION; ADULT; ALERTNESS; ANGER; ANXIETY; ARTICLE; ATTENTION; BEHAVIOR; BEHAVIOR DISORDER; BENTON VISUAL RETENTION TEST; CATEGORY FLUENCY TEST; COGNITION; CONTINUOUS PERFORMANCE TEST IDENTICAL PAIRS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIGIT MEMORY TASK; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; REY AUDITORY VERBAL LEARNING TEST; SADNESS; TASK PERFORMANCE; VISUAL ANALOG SCALE; AFFECT; AGONISTS; BLOOD; DRUG EFFECTS; DRUG THERAPY; LEARNING; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AFFECT; ANXIETY; COGNITION; CROSS-OVER STUDIES; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; TREATMENT OUTCOME; VERBAL LEARNING; YOUNG ADULT;

EID: 84921527256     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.12.007     Document Type: Article

References (63)

1. Bado P., Madeira C., Vargas-Lopes C., Moulin T.C., Wasilewska-Sampaio A.P., Maretti L., et al. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacol Berl 2011, 218:461-470.
2. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. JNeurosci 2002, 22:6713-6723.
3. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A 2013, 110:E2400-E2409.
4. Bruno M.A., Mufson E.J., Wuu J., Cuello A.C. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. JNeuropathol Exp Neurol 2009, 68:1309-1318.
5. Cho H.S., Perry E., Gunduz-Bruce H., D'Souza D.C. The ketamine paradigm in humans: relevance to psychotic disorders. Glutamate in neuropsychiatric disorders 2008, 99-131. Research Signpost, Kerala, India. U. Heresco-Levy, D.C. Javitt (Eds.).
6. Colombo G., Grant K.A. NMDA receptor complex antagonists have ethanol-like discriminative stimulus effects. Ann N Y Acad Sci 1992, 654:421-423.
7. D'Souza D.C., Gil R., Cassello K., Morrissey K., Abi-Saab D., White J., et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 2000, 47:450-462.
8. Feld G.B., Lange T., Gais S., Born J. Sleep-dependent declarative memory consolidation-unaffected after blocking NMDA or AMPA receptors but enhanced by NMDA coagonist D-cycloserine. Neuropsychopharmacology 2013, 38:2688-2697.
9. File S.E., Fluck E., Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. JClin Psychopharmacol 1999, 19:506-512.
10. Gardoni F., Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006, 545:2-10.
11. Gelfin E., Kaufman Y., Korn-Lubetzki I., Bloch B., Kremer I., Javitt D.C. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int J Neuropsychopharmacol 2012, 15:543-549.
12. Goff D.C. Bitopertin: the good news and bad news. JAMA Psychiatry 2014, 71:621-622.
13. Greenberg W.M., Benedict M.M., Doerfer J., Perrin M., Panek L., Cleveland W.L., et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. JPsychiatr Res 2009, 43:664-670.
14. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
15. Hashimoto K., Fujita Y., Ishima T., Chaki S., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008, 18:414-421.
16. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindström L.H., Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:767-769.
17. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003, 60:572-576.
18. Heresco-Levy U., Shoham S., Javitt D.C. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis. Mov Disord 2013, 28:419-424.
19. Heresco-Levy U., Gelfin G., Bloch B., Levin R., Edelman S., Javitt D.C., et al. Arandomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013, 16:501-506.
20. Heresco-Levy U., Javitt D.C. Glutamate in neuropsychiatric disorders 2008, Research Signpost, Trivandrum, Kerala, India.
21. Hoffmann-La Roche Astudy of bitopertin (RO4917838) in combination with selective serotonin reuptake inhibitors in patients with obsessive-compulsive disorder. ClinicalTrials.gov 2013, National Library of Medicine (US), Bethesda (MD). http://clinicaltrials.gov/show/NCT01674361.
22. Huang C.C., Wei I.H., Huang C.L., Chen K.T., Tsai M.H., Tsai P., et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 2013, 74:734-741.
23. Huang Y.J., Lin C.H., Lane H.Y., Tsai G.E. NMDA Neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease. Curr Neuropharmacol 2012, 10:272-285.
24. Kantrowitz J.T., Malhotra A.K., Cornblatt B.A., Silipo G., Balla A., Suckow R.F., et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010, 121:125-130.
25. Kantrowitz J.T., Javitt D.C. N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res Bull 2010, 83:108-121.
26. Kew J.N., Koester A., Moreau J.L., Jenck F., Ouagazzal A.M., Mutel V., et al. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. JNeurosci 2000, 20:4037-4049.
27. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988, 241:835-837.
28. Krystal J.H., Sanacora G., Duman R.S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013, 73:1133-1141.
29. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005, 62:985-994.
30. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
31. Kuriyama K., Honma M., Koyama S., Kim Y. D-cycloserine facilitates procedural learning but not declarative learning in healthy humans: a randomized controlled trial of the effect of D-cycloserine and valproic acid on overnight properties in the performance of non-emotional memory tasks. Neurobiol Learn Mem 2011, 95:505-509.
32. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
33. Lai C.H., Lane H.Y., Tsai G.E. Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naïve patient with major depression. Biol Psychiatry 2012 Feb, 71(4):e9-e10. Epub 2011 Dec 15. 10.1016/j.biopsych.20122.10.034.
34. Lane H.Y., Lin C.H., Green M.F., Hellemann G., Huang C.C., Chen P.W., et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013, 70:1267-1275.
35. Lara D.R., Bisol L.W., Munari L.R. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013, 16:2111-2117.
36. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987, 334:1-100.
37. Lin C.H., Chen P.K., Chang Y.C., Chuo L.J., Chen Y.S., Tsai G.E., et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2014, 75:678-685.
38. Lovinger D.M., White G., Weight F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989, 243:1721-1724.
39. Malkesman O., Austin D.R., Tragon T., Wang G., Rompala G., Hamidi A.B., et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol 2012, 15:1135-1148.
40. Matsui T., Sekiguchi M., Hashimoto A., Tomita U., Nishikawa T., Wada K. Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. JNeurochem 1995, 65:454-458.
41. Moghaddam B., Krystal J.H. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 2012, 38:942-949.
42. Mor'e L., Gravius A., Nagel J., Valastro B., Greco S., Danysz W. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav Pharmacol 2008, 19:724-734.
43. Moritz S., Heeren D., Andresen B., Krausz M. An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia. Psychiatry Res 2001, 101:23-31.
44. Muir J.L., Everitt B.J., Robbins T.W. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacol Berl 1995, 118:82-92.
45. Neumeister A., Carson R., Henry S., Planeta-Wilson B., Binneman B., Maguire R.P., et al. Cerebral metabolic effects of intravenous glycine in healthy human subjects. JClin Psychopharmacol 2006, 26:595-599.
46. Nilsson M., Carlsson A., Carlsson M.L. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. JNeural Transm 1997, 104:1195-1205.
47. Onur O.A., Schlaepfer T.E., Kukolja J., Bauer A., Jeung H., Patin A., et al. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry 2010, 67:1205-1211.
48. Palmer C., Ellis K.A., O'Neill B.V., Croft R.J., Leung S., Oliver C., et al. The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls. Hum Psychopharmacol 2008, 23:151-159.
49. Papouin T., Ladépêche L., Ruel J., Sacchi S., Labasque M., Hanini M., et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
50. Parwani A., Weiler M.A., Blaxton T.A., Warfel D., Hardin M., Frey K., et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacol Berl 2005, 183:265-274.
51. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. JClin Psychopharmacol 2008, 28:631-637.
52. Rush A.J. Ketamine for treatment-resistant depression: ready or not for clinical use?. Am J Psychiatry 2013, 170:1079-1081.
53. Schell M.J., Molliver M.E., Snyder S.H. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A 1995, 92:3948-3952.
54. Schizophrenia Working Group of the Psychiatric Genomics C Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
55. Schwartz B.L., Hashtroudi S., Herting R.L., Handerson H., Deutsch S.I. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991, 41:1341-1343.
56. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
57. Smith E.G., Deligiannidis K.M., Ulbricht C.M., Landolin C.S., Patel J.K., Rothschild A.J. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. JClin Psychiatry 2013, 74:966-973.
58. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R, Patient Edition/Non-patient Edition, (SCID-P/SCID-NP) 1990, American Psychiatric Press, Inc., Washington, D.C.
59. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010, 16:522-537.
60. Tsai G.E., Lane H.Y., Vandenberg C.M., Liu Y.C., Tsai P., Jann M.W. Disposition of D-serine in healthy adults. JClin Pharmacol 2008, 48:524-527.
61. Yoshida T., Ishikawa M., Iyo M., Hashimoto K. Serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in healthy subjects. Open Clin Chem J 2012, 5:7-12.
62. Yoshida T., Ishikawa M., Niitsu T., Nakazato M., Watanabe H., Shiraishi T., et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012, 7:e42676.
63. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., et al. Adouble-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.